Sunshine Biopharma (SBFM) Net Margin (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Net Margin came in at 16.88% in Q2 2026, up 1447.0% on a YoY basis from 1.09% in Q2 2025, and down 9.79% quarter-over-quarter from 15.38% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Net Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Net Margin for 10 consecutive years, with 16.88% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin rose 1447.0% year-over-year to 16.88%; the trailing twelve-month figure through Jun 2026 stood at 16.5% (up 410.0% YoY), and the FY2025 full-year result was 16.46%, down 174.0% from the prior year.
- Net Margin slipped to 16.88% in Q2 2026 per SBFM's latest filing, from 15.38% in the prior quarter.
- Across five years, Net Margin topped out at 9.39% in Q3 2025 and bottomed at 1097.09% in Q3 2022.
- Historically, Net Margin has averaged 184.56% across 5 years, with a median of 18.07% in 2024.
- The widest YoY moves for Net Margin: up 1443245 bps in 2022, down 138054 bps in 2022.
- Over 5 years, Net Margin stood at 596.78% in 2022, then jumped by 97 bps to 15.78% in 2023, then sank by 43 bps to 22.49% in 2024, then decreased by 11 bps to 24.96% in 2025, then surged by 32 bps to 16.88% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 16.88%, 15.38%, and 24.96% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.81 Bn | 39.16 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.90 Bn | 9.73 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.35 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.32 Bn | 479.50 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.12 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 997.70 Mn | 707.58 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 395.89 Mn | 354.64 Mn | 17.15 Mn | 11.04% |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | -16.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.88% |
| Mar 31, 2026 | -15.38% |
| Dec 31, 2025 | -24.96% |
| Sep 30, 2025 | -9.39% |
| Jun 30, 2025 | -31.36% |
| Mar 31, 2025 | -13.25% |
| Dec 31, 2024 | -22.49% |
| Sep 30, 2024 | -14.20% |
| Jun 30, 2024 | -19.11% |
| Mar 31, 2024 | -17.02% |
| Dec 31, 2023 | -15.78% |
| Sep 30, 2023 | -10.94% |
| Jun 30, 2023 | -16.22% |
| Mar 31, 2023 | -34.79% |
| Dec 31, 2022 | -596.78% |
| Sep 30, 2022 | -1,097.09% |
| Jun 30, 2022 | -358.51% |
| Mar 31, 2022 | -1,007.98% |
| Dec 31, 2021 | 783.75% |
| Sep 30, 2021 | -8,018.47% |